PhRMA Endorses Proposed AMP Rule In Principle But Perhaps Not In Practice
Executive Summary
The Pharmaceutical Research and Manufacturers of America is supporting CMS' proposal to broadly define the "retail class of trade" for the purpose of calculating Medicaid average manufacturer prices, but raises concern about manufacturers' potential responsibility to track the various sales and price concessions through the drug distribution network
You may also be interested in...
ASPs For Bundled Drugs Might Be Improved With “Exceptions” Process – MedPAC
CMS should consider creating a process to allow revisions of Part B average sales prices for drugs sold through bundled arrangements, to enhance the accuracy of ASPs, the Medicare Payment Advisory Commission suggests in comments to CMS
ASPs For Bundled Drugs Might Be Improved With “Exceptions” Process – MedPAC
CMS should consider creating a process to allow revisions of Part B average sales prices for drugs sold through bundled arrangements, to enhance the accuracy of ASPs, the Medicare Payment Advisory Commission suggests in comments to CMS
Medicaid AMPs Exclude PBM Discounts Outside Of Mail Order – Final Rules
CMS has been persuaded to exclude pharmacy benefit manager price concessions, other than mail-order, from Medicaid AMPs, because PBMs do not take possession of drug products in most cases nor are their financial transactions easily tracked by manufacturers